




FOIA PTO-1449 INFORMATION DISCLOSURE CITATION		Attorney Docket: 3828-4000US1		Serial No.: 09/995,522	
		Applicant: Cohava GELBER			
		Filing Date: November 28, 2001		Group Art Unit: To Be Assigned	
U.S. PATENT DOCUMENTS					
Examiner Initial		Patent Number	Issue Date	Name	Class
FOREIGN PATENT DOCUMENTS					
Examiner Initial		Patent Number	Publication Date	Country	Class
OTHER DOCUMENTS (Including Author, Title, Date, etc.)					
LA	1	D. Avichezer et al., 1977, "Immunoreactivities of Polyclonal and Monoclonal Anti-T and Anti-Tn Antibodies with Human Carcinoma Cells, Grown <i>In Vitro</i> and in a Xenograft Model", <u>Int. J. Cancer</u> , 72:119-127.			
	2	S. Mioti et al., 1999, "Level of Anti-Mouse-Antibody Response Induced by Bi-Specific Monoclonal Antibody OC/TR in Ovarian-Carcinoma Patients is Associated with Longer Survival", <u>Int. J. Cancer</u> , 84:62-68.			
	3	J.A. Francisco et al., 1997, "In vivo Efficacy and Toxicity of a Single-Chain Immunotoxin Targeted to CD40", <u>Blood</u> , 89:4493-4500.			
	4	C.F.M. Molthoff et al., 1997, "Escalating Protein Doses of Chimeric Monoclonal Antibody Mov18 Immunoglobulin G in Ovarian Carcinoma Patients: A Phase I Study", <u>CANCER Supplement</u> , 80:2712-2720.			
	5	E. Kievit et al., 1997, "Determination of Tumor-Related Factors of Influence on the Uptake of the Monoclonal Antibody 323/A3 in Experimental Human Ovarian Cancer", <u>Int. J. Cancer</u> , 71:237-245.			
	6	K.O. Lloyd et al., 1997, "Isolation and Characterization of Ovarian Cancer Antigen CA 125 using a New Monoclonal Antibody (VK-8): Identification as a Mucin-Type Molecule", <u>Int. J. Cancer</u> , 71:842-850.			
	7	A. van Dalen, 1999, "BR-MA, OM-MA, GI-MA and CEA: Clinical Evaluation Using the IMMULITE Analyzer", <u>Tumor Biology</u> , 20:117-129.			
	8	G. Gebauer et al., 1999, "IMMULITE® OM-MA Assay: A Useful Diagnostic Tool in Patients with Benign and Malignant Ovarian Tumors", <u>Anticancer Research</u> , 19:2535-2536.			
	9	S. Ozaki et al., 1997, "Immunotherapy of Multiple Myeloma with a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24", <u>Blood</u> , 90:3179-3186.			
	10	S.P. Treon et al., 1999, "Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by Dexamethasone", <u>Blood</u> , 93:1287-1298.			
	11	K. Ono et al., 1999, "The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity", <u>Mol. Immunology</u> , 36:387-395.			
	12	G. Teoh et al., 1998, "The 86-kD Subunit of Ku Autoantigen Mediates Homotypic and Heterotypic Adhesion of Multiple Myeloma Cells", <u>J. Clin. Invest.</u> , 101:1379-1388.			
	13	W.C.A.M. Buijs et al., 1998, "Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration", <u>Eur. J. Nuclear Medicine</u> , 25:1552-1561.			
LA	14	M.A. Bookman, 1998, "Biological Therapy of Ovarian Cancer: Current Directions", <u>Seminars in Oncology</u> , 25:381-396.			
Examiner		Date Considered			
		7/11/02			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					



FORM PTO-1449 INFORMATION DISCLOSURE CITATION		Attorney Docket: 3828-4000US1	Serial No.: 09/995,522	RECEIVED			
		Applicant: Cohava GELBER					
		Filing Date: November 28, 2001	Group Art Unit: To Be Assigned	MAR 26 2002			
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent Number	Issue Date	Name	Class	Class	Filing Date
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Patent Number	Publication Date	Country	Class	Sub-Class	Translation
							<input type="checkbox"/> Yes <input type="checkbox"/> No
							<input type="checkbox"/> Yes <input type="checkbox"/> No
OTHER DOCUMENTS (Including Author, Title, Date, etc.)							
LAP	15	M. Kawata et al., 1998, "Detection of Epithelial Ovarian-Cancer-Associated Antigens Involved in Immune Complexes by Monoclonal Antibodies", <u>Tumor Biology</u> , 19:1-11.					
	16	S.A. McQuarrie et al., 1997, "Pharmacokinetics and radiation dosimetry of ⁹⁹ Tc ^m -labelled monoclonal antibody B43.13 in ovarian cancer patients", <u>Nuclear Medicine Communications</u> , 18:878-886.					
	17	E. Kievit et al., 1997, "Comparison of the Biodistribution and the Efficacy of Monoclonal Antibody 323/A3 Labeled with Either ¹³¹ I or ¹⁸⁶ Re in Human Ovarian Cancer Xenografts", <u>Int. J. Radiation Oncology Biol. Phys.</u> , 38:813-823.					
	18	M. Hartman et al., 1999, "MUC1 Isoform Specific Monoclonal Antibody 6E6/2 Detects Preferential Expression of the Novel MUC1/Y Protein in Breast and Ovarian Cancer", <u>Int. J. Cancer</u> , 82:256-267.					
	19	M.L. Grossbard et al., 1998, "Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma", <u>British Journal of Haematology</u> , 102:509-515.					
	20	H. Bertz et al., 1997, "Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect", <u>Leukemia</u> , 11:281-283.					
	21	J.L. Hornick et al., 1997, "Chimeric CLL-1 Antibody Fusion Proteins Containing Granulocyte-Macrophage Colony-Stimulating Factor or Interleukin-2 with Specificity for B-Cell Malignancies Exhibit Enhanced Effector Functions while Retaining Tumor Targeting Properties", <u>Blood</u> , 89:4437-4447.					
	22	D.G. Maloney et al., 1999, "Antibody Therapy for Treatment of Multiple Myeloma", <u>Seminars in Hematology (Suppl.)</u> , 36:30-33.					
	23	V. Nuessler et al., 1997, "Functional P-gp expression in multiple myeloma patients at primary diagnosis and relapse or progressive disease", <u>Leukemia (Suppl.)</u> , 11:S10-S14.					
	24	G.J. Ossenkoppele, 1997, "Treatment of Multiple Myeloma in Elderly Patients", <u>Drugs & Aging</u> , 11:152-164.					
	25	T.H. Totterman et al., 1998, "Targeted Superantigens for Immunotherapy of Haematopoietic Tumors", <u>Vox Sanguinis</u> , 74:483-487.					
	26	M.G. Rosenblum et al., 1999, "Phase I Study of ⁹⁰ Y-labeled B72.3 Intraperitoneal Administratoion in Patients with Ovarian Cancer: Effect of Dose and EDTA Coadministration on Pharmacokinetics and Toxicity", <u>Clinical Cancer Research</u> , 5:953-961.					
	27	R.H.M. Verheijen et al., 1999, "CA 125: fundamental and clinical aspects", <u>Seminars in Cancer Biology</u> , 9:117-124.					
	28	G. Fleckenstein et al., 1998, "Monoclonal antibodies in solid tumours: approaches to therapy with emphasis on gynaecological cancer", <u>Medical Oncology</u> , 15:212-221.					
LX	29	E. Kievit et al., 1998, "[¹⁸⁶ Re]-labeled Mouse and Chimeric Monoclonal Antibody 323/A3: A Comparison of the Efficacy in Experimental Human Ovarian Cancer", <u>Nuclear Medicine & Biology</u> , 25:37-45.					
Examiner		Date Considered		7/11/03			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							



INFORMATION DISCLOSURE CITATION	Attorney Docket: 3828-4000US1	Serial No.: 09/995,522	RECEIVED MAR 25 2002 TECH CENTER 1500 2900
	Applicant: Cohava GELBER		
	Filing Date: November 28, 2001	Group Art Unit: To Be Assigned	

U.S. PATENT DOCUMENTS

Examiner Initial	Patent Number	Issue Date	Name	Class	Filing Date

FOREIGN PATENT DOCUMENTS

Examiner Initial	Patent Number	Publication Date	Country	Class	Sub-Class	Translation
						<input type="checkbox"/> Yes <input type="checkbox"/> No
						<input type="checkbox"/> Yes <input type="checkbox"/> No

OTHER DOCUMENTS (Including Author, Title, Date, etc.)

LA	30	S. Nicholson et al., 1998, "Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: A matched analysis", <u>Oncology Reports</u> , 5:223-226.
	31	B.C. Schultes et al., 1998, "Anti-idiotype induction therapy: anti-CA125 antibodies (AB ₃) mediated tumor killing in patients treated with Ovarex mAB B43.13 (Ab ₁), <u>Cancer Immunol. Immunother</u> , 46:201-212.
	32	M. Jojovic et al., 1998, "Epithelial glycoprotein-2 expression is subject to regulatory processes in epithelial-mesenchymal transitions during metastases: an investigation of human cancers transplanted into severe combined immunodeficient mice", <u>Histochemical Journal</u> , 30:723-729.
	33	C. Kosmas et al., 1998, "Monoclonal Antibody Targeting of Ovarian Carcinoma", <u>Oncology</u> , 55:435-446.
	34	M.F. Federici et al., 1999, "Selection of Carbohydrate Antigens in Human Epithelial Ovarian Cancers as Targets for Immunotherapy: Serous and Mucinous Tumors Exhibit Distinctive Patterns of Expression", <u>Int. J. Cancer</u> , 81:193-198.
	35	W.G. McCluggage et al., 1998, "Immunocytochemical staining of ovarian cancer cyst aspirates with monoclonal antibody against inhibin", <u>Cytopathology</u> , 9:336-342.
	36	H.C.T. VanZaenen et al., 1998, "Blocking Interleukin-6 Activity with Chimeric Anti-IL6 Monoclonal Antibodies in Multiple Myeloma: Effects on Soluble IL6 Receptor and Soluble gp 130", <u>Leukemia and Lymphoma</u> , 31:551-558.
	37	V.L. Reichardt et al., 1997, "Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma", <u>Biol. Blood and Marrow Transplant</u> , 3:157-63.
	38	N.L. Smith et al., 1999, "Immunohistochemically detecting target antigens in patient biopsies for tailoring monoclonal antibody based cancer therapy", <u>Human Antibodies</u> , 9:61-65.
	39	E. Harlow et al., 1988, "Labeling Antibodies", <u>Antibodies: A Laboratory Manual</u> , pp. 321-631.
	40	N.S. Greenspan et al., 1999, "Defining epitopes: It's not as easy as it seems", <u>Nature Biotechnology</u> , 17:936-937.
	41	P. Knight, 1989, "The Carbohydrate Frontier", <u>Biotechnology</u> , 7:35-40.
	42	J.M. Cruse et al., 1995, <u>Illustrated Dictionary of Immunology</u> , p. 22.
WA	43	W. Paul, 1993, <u>Fundamental Immunology</u> , Raven Press, NY Chpt 8, p. 242.

Examiner	Date Considered 9/11/03
----------	-------------------------

EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
-----------	---